Hai Yi Ma

Dr. Hai Yi Ma is an Independent Director at TLC BioSciences Corp., an Independent Director at Steminent Biotherapeutics, Inc., an Independent Director at Lumosa Therapeutics Co., Ltd. and an Independent Director at BioGend Therapeutics Co., Ltd. She is on the Board of Directors at TLC BioSciences Corp., Steminent Biotherapeutics, Inc., Lumosa Therapeutics Co., Ltd., Obigen Pharma, Inc., BioGend Therapeutics Co., Ltd., Formosa Pharmaceuticals, Inc., TWi Pharmaceuticals Holding, Inc. and Taiwan Bio Industry Organization.
Dr. Ma was previously employed as an Independent Director by Crown Bioscience International, a Chairman-Pharmaceutical Production Committee by Pharmaceutical Research & Manufacturers of America, an Independent Director by Crown Bioscience, Inc., a Manager-Electronic Materials Plant by Monsanto Co., a VP-Pharmaceutical Technology & Operations by Syntex Corp., and a Founder by Vivo Capital LLC.
She also served on the board at Reber Genetics Co., Ltd., TWi Pharmaceuticals, Inc. and ScinoPharm Taiwan Ltd. She received her undergraduate degree from National Taiwan University, a graduate degree from the University of Iowa and a doctorate degree from Lehigh University.